shelf(0)

No. 015 · GH & Growth · Growth Hormone

Hexarelin

ExamorelinEP-23905

B Tier B · Small human studies how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
Hexarelin (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER B — Human data limited to small, open-label or pharmacokinetic studies.

Human data are limited to small pharmacological studies; no approved use.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

The most potent synthetic GHRP, producing the largest single GH pulse among its class. Its use is limited by desensitization at prolonged high doses and notable cortisol/prolactin elevation.

Research status Phase I/II clinical trials; documented receptor desensitization with prolonged use

04

Mechanism

Hexarelin is a synthetic hexapeptide and the most potent GHS-R1a agonist, producing the largest acute GH pulse among all GHRPs. It acts through both pituitary and hypothalamic pathways to amplify GH release. It also binds the CD36 scavenger receptor on cardiomyocytes, conferring cardioprotective effects independent of GH.

05

Effects reported in research

Reported outcomes, not promises. Human data are limited to small studies, and many of these findings are preclinical.

  • Strongest GH release among GHRPs
  • Cardioprotective signaling
  • Increased IGF-1 output
  • Enhanced fat oxidation
06

Safety & unknowns

Human trial data available. Desensitization of GH response occurs with prolonged daily use. Elevates cortisol and prolactin more than other GHRPs. Common side effects: flushing, hunger, water retention. Not FDA-approved.

Unknowns. No randomized controlled trials have been published. Small studies cannot detect uncommon or long-term harms.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [0]

No studies cited for this entry yet.

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). Hexarelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/hexarelin/

$ cite --format=bibtex 
@misc{peptidemeta-hexarelin,
  title = {Hexarelin},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/hexarelin/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open